Table 1

Baseline characteristics and admission investigations of patients presenting with ST-elevation myocardial infarction comparing the NR group with the control group

NRP value
Age (years)62±1370±130.004
Male104 (70)14 (58)0.3
 Diabetes mellitus21 (14)3 (13)0.8
 Hypertension44 (30)12 (50)0.047
 Hypercholesterolaemia35 (23)6 (25)0.9
 Ischaemic heart disease26 (17)4 (17)0.9
 Smoking current62 (42)5 (22)0.06
 Ex46 (31)8 (36)0.6
Examination on admission
 Weight (kg)85±2077±140.087
 Heart rate (beats/min)75±1978±200.5
 Systolic blood pressure (mm Hg)138±28151±300.03
 Diastolic blood pressure (mm Hg)80±1680±180.9
 Blood glucose8.0±3.38.6±3.60.4
Killip class
 I118 (79)15 (63)0.056
 II25 (17)7 (29)
 III3 (2)0 (0)
 IV3 (2)2 (8)
Medication use prior to admission
 Aspirin25 (17)4 (17)1.0
 Dual antiplatelet therapy2 (1)0 (0)0.6
 Anticoagulation warfarin7 (5)1 (4)0.9
 DOAC1 (1)1 (4)0.1
 Statin42 (28)8 (33)0.6
Time to treatment
 Symptoms to door time (min)511±915681±11850.4
 Symptoms to balloon time (min)543±918720±11950.4
 Door to balloon time (min)32±1439±410.1
 Symptoms to aspirin time (min)435±941628±12680.4
 Symptoms to P2Y12 antagonist (min)510±923656±12050.5
Inpatient investigationsNormal range
Haemoglobin (g/L)(135–175)142±18135±160.066
Neutrophil (×109/L)(2.0–7.7)11.1±11.511.5±4.10.8
Platelet (×109/L)(150–400)248±95216±730.1
Creatinine (μmol/L)(50–120)79±2291±320.038
eGFR (mL/min)(>90)89±2678±320.059
Albumin (g/L)(35–55)36±534±40.096
C reactive protein(<10)19±3616±300.8
NT-proBNP (pg/mL)(<400)1556±24993305±77080.047
Resolution of ECG ST change88 (64)12 (57)0.530
Left ventricular dysfunction
 None62 (43)7 (29)0.5
 Mild46 (32)8 (33)
 Moderate29 (20)6 (25)
 Severe9 (6)3 (12.5)
  • Continuous variables are expressed as mean±SD with correlation investigated with one-way analysis of variance. Categorical variables are expressed as number (percentage), with correlation investigated with χ2 test. P<0.05 was deemed significant; however, p<0.1 (bold) suggested further analysis was required.

  • DOAC, direct-acting oral anticoagulant; eGFR, estimated glomerular filtration rate; NR, no reflow; NT-proBNP, N-terminal pro-B-type natriuretic peptide.